Antiretroviral therapy for prevention of HIV and tuberculosis: A promising intervention but not a panacea

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue SUPPL. 2, 2013, Pages

  McNairy, Margaret L ^a,b   Howard, Andrea A ^a   El Sadr, Wafaa M ^a  

^a Mailman School of Public Health ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CIRCUMCISION; DEVELOPED COUNTRY; DIRECTLY OBSERVED THERAPY; HETEROSEXUALITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION CONTROL; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; THERAPY DELAY; TUBERCULIN TEST; TUBERCULOSIS; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; FAMILY CHARACTERISTICS; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MODELS, THEORETICAL; RISK; TUBERCULOSIS;

EID: 84880202383     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182986fc6     Document Type: Article

References (86)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N EnglJ Med. 2010; 363:2587-2599.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
4. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
5. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001270.
6. HIV Causal Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis. 2012;54:1364-1372.
7. Cohen MS, Holmes C, Padian N, et al. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff (Millwood). 2012;31:1439-1449.
8. Barnighausen T, Bloom DE, Humair S. Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci USA. 2012;109:21271-21276.
9. Lawn SD, Harries AD, Williams BG, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis. 2011;15:571-581.
10. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18:81-88.
11. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:e11068.
12. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532-539.
13. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190:879-885.
14. Tanser F, Barnighausen T, Grapsa E, et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966-971.
15. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med. 1994;154: 1971-1976.
16. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
17. Del Romero J, Castilla J, Hernando V, et al. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010;340:c2205.
18. Melo MG, Santos BR, De Cassia Lira R, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis. 2008;35:912-915.
19. Jia Z, Ruan Y, Li Q, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet. 2012. doi: 10.1016/S0140-6736(12)61898-4.
20. Sullivan P, Kayitenkore K, Chomba E, et al. Reduction of HIV transmission risk and high risk sex while prescribing ART: results form discordant couples in Rwanda and Zambia. Abstract 52bLB. Paper presented at: Conference on Retrroviruses and Opportunistic Infections; 2009; Montreal, Canada.
21. Lu W, Zeng G, Luo J, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr. 2010;55:232-238.
22. Anglemyer A, Rutherford G, Egger M, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database System Rev. 2011;5:CD009153.
23. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
24. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.
25. Meyer-Rath G, Over M. HIV treatment as prevention: modelling the cost of antiretroviral treatment-state of the art and future directions. PLoS Med. 2012;9:e1001247.
26. Barnighausen T, Salomon JA, Sangrujee N. HIV treatment as prevention: issues in economic evaluation. PLoS Med. 2012;9:e1001263.
27. HIV Modeling Group Consortium. HIV treatment as prevention: models, data, and questions-towards evidence-based decision-making. PLoS Med. 2012;9:e1001259.
28. World Health Organization. Global Tuberculosis Control 2009: Epidemiology, Strategy, and Financing. Geneva: WHO; 2009.
29. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d' Ivoire. Lancet. 1995;345:607-610.
30. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143-152.
31. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. NEngl JMed. 2010;362: 697-706.
32. Manosuthi W, Chottanapand S, Thongyen S, et al. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43: 42-46.
33. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr. 2009;50:148-152.
34. Sanguanwongse N, Cain KP, Suriya P, et al. Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr. 2008;48:181-189.
35. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059-2064.
36. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631-636.
37. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441-1448.
38. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:1588-1598.
39. Zachariah R, Bemelmans M, Akesson A, et al. Reduced tuberculosis case notification associated with scaling up antiretroviral treatment in rural Malawi. Int J Tuberc Lung Dis. 2011;15:933-937.
40. Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr. 2011;56:263-269.
41. Williams BG, Granich R, De Cock KM, et al. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci USA. 2010;107:19485-19489.
42. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363: 257-265.
43. Wood R, Lawn SD. Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic. Curr HIV Res. 2011;9:383-392.
44. Middelkoop K, Wood R, Bekker LG. The impact of antiretroviral treatment programs on tuberculosis notification rates. Int J Tuberc Lung Dis. 2011;15:1714; author's reply 1714-1715.
45. Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am JRespir Crit Care Med. 2010;182:1080.
46. Teasdale C, Mugisha V, Wang C, et al. Determinants of mortality and loss to follow-up among adult patients in pre-ART care and on ART in Rwanda. Abstract number Y-132. Paper presented at: Conference of Retroviruses and Opportunistic Infections; 2013; Atlanta, GA.
47. De Cock KM, El-Sadr WM. When to start ART in Africa-an urgent research priority. N Engl J Med. 2013;368:886-889.
48. Sabin C, Cooper D, Collins S, et al. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. AIDS. 2013. doi: 10.1097/QAD.0b013e328360d546.
49. Cohen MS, Muessig KE, Smith MK, et al. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS. 2012;26: 1585-1598.
50. Lahuerta M, Lima J, Nuwagaba-Biribonwoha H, et al. Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PLoS One. 2012;7:e37125.
51. Lahuerta M, Ue F, Hoffman S, et al. The problem of late ART initiation in sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved. 2013;24:359-383.
52. WHO, UNAIDS, USAID. Global HIV/AIDS Response, Epidemic Update and Health Sector Progress Torwards Universal Access-Progress Report 2011. Geneva: WHO; 2011.
53. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health. 2002;92:388-394.
54. McNairy ML, Cohen M, El-Sadr WM. Antiretroviral therapy for prevention is a combination strategy. Curr HIV/AIDS Rep. 2013. doi: 10.1007/s11904-013-0152- 1.
55. Were W, Mermin J, Bunnell R, et al. Home-based model for HIV voluntary counselling and testing. Lancet. 2003;361:1569.
56. Lugada E, Millar D, Haskew J, et al. Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS One. 2010;5:e12435.
57. McNairy ML, El-Sadr WM. The HIV care continuum: no partial credit given. AIDS. 2012;26:1735-1738.
58. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8:e1001056.
59. Mugglin C, Estill J, Wandeler G, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2012. doi: 10.1111/j.1365-3156.2012.03089.x.
60. Vital signs: HIV prevention through care and treatment-United States. MMWR Morb Mortal Wkly Rep. 2011;60:1618-1623.
61. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793-800.
62. Marks G, Gardner LI, Craw J, et al. The spectrum of engagement in HIV care: do more than 19% of HIV-infected persons in the US have undetectable viral load? Clin Infect Dis. 2011;53:1168-1169; author's reply 1169-1170.
63. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-656.
64. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.
65. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657-666.
66. World Health Organization. Joint Strategic Action Framework to Accelerate the Scale-up of Voluntary Medical Male Circumcision for HIV Prevention in Eastern and Southern Africa. Geneva: WHO; 2011.
67. Mutabazi V, Kaplan SA, Rwamasirabo E, et al. One arm, open label, prospective, cohort field study to assess the safety and efficacy of the PrePex device for scale up of non-surgical circumcision when performed by nurses in resource limited settings for HIV prevention. J Acquir Immune Defic Syndr. 2013 [Epub ahead of print].
68. Bitega JP, Ngeruka ML, Hategekimana T, et al. Safety and efficacy of the PrePex device for rapid scale-up of male circumcision for HIV prevention in resource-limited settings. J Acquir Immune Defic Syndr. 2011;58: e127-e134.
69. Marrazzo J, Ramjee G, Nair G, et al.; and the VOICE Study Team. Preexposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003), Abstract 26LB. Paper presented at; Conference on Retroviruses and Opportunistic Infections; 2013; Atlana, GA.
70. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
71. World Health Organization. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living With HIV in Resource-Constrained Settings. Geneva: WHO; 2011.
72. World Health Organization. The five elements of DOTS. Available at: http://www.who.int/tb/dots/whatisdots/en/index.html. Accessed March 12, 2013.
73. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet. 2006;368:1254-1259.
74. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191:150-158.
75. Lawn SD, Wood R, De Cock KM, et al. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10: 489-498.
76. HIV Prevention Trials Network. 2013. Available at: http://www.hptn. org/. Accessed March 22, 2013.
77. De Cock KM, El-Sadr WM, Ghebreyesus TA. Game changers: why did the scale-up of HIV treatment work despite weak health systems? J Acquir Immune Defic Syndr. 2011;57(suppl 2):S61-S63.
78. Babiker AG, Emery S, Fatkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials. Apr 30 2012.
79. Health SADo. National Antiretroviral Treatment Guidelines. Pretoria, South Africa: South African National Department of Health; 2010.
80. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services; 1998-2012. Washington, DC: Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/guidelines/archive/adult-and-adolescent-guidelines/.
81. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. Jan 19 2000;283(3):381-390.
82. Report of the NIH panel to define principles of therapy of HIV infection. Ann Intern Med. 1998;128(12 Pt 2):1057-1078.
83. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
84. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
85. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996;276:146-154.
86. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva: WHO; 2006.